Thomson et al. in a systematic review on screening a cohort of mixed aetiology HCC came to the conclusion that screening ultrasound is cost effective when it is offered to patients with an AFP value more than 20 ng/ml [19]. This evidence concerns the gene AFP and hepatocellular carcinoma.